LncRNA CASC11 was downregulated in coronary artery disease and inhibits transforming growth factor-β1

Abstract

Objective: To investigate the involvement of long non-coding RNA (lncRNA) Cancer Susceptibility 11 (CASC11) in patients with coronary artery disease (CAD). Methods: This case-control study enrolled patients with CAD and age-and sex-matched healthy control subjects. The plasma levels of lncRNA CASC11 and transforming growth factor-beta 1 (TGF-b1) were measured. Diagnostic values of lncRNA CASC11 and TGF-b1 for CAD were determined using receiver operating characteristic curve analysis. Correlations between plasma levels of lncRNA CASC11 and TGF-b1 were analysed using linear regression. Results: The study enrolled 82 patients with CAD and 82 healthy controls. Plasma levels of lncRNA CASC11 were downregulated in patients with CAD, while plasma TGF-b1 levels were upregulated in patients with CAD, compared with healthy controls. Plasma levels of lncRNA CASC11 and TGF-b1 distinguished patients with CAD from healthy controls and were inversely correlated in both groups. LncRNA CASC11 over-expression mediated the downregulation of TGF-b1 in human primary coronary artery endothelial cells, while TGF-b1 over-expression showed no significant effects on lncRNA CASC11 levels. An 8-year follow-up study showed that low lncRNA CASC11 levels were closely correlated with a higher mortality rate in patients with CAD. Conclusion: LncRNA CASC11 is downregulated in CAD and inhibits TGF-b1.

LncRNA CASC11 upregulation promotes HDAC4 to alleviate oxidized low‐density lipoprotein‐induced injury of cardiac microvascular endothelial cells

“…A prior study has discovered the downregulation of lncRNA CASC11 in CAD 15 . Therefore, we detected the expression pattern of CASC11 in CMECs and found that the expression levels of CASC11 were decreased with the increase in ox‐LDL concentration ( p < 0.01, Figure 2A).…”

“…LncRNA cancer susceptibility 11 (CASC11) is a well‐documented oncogene signature in a variety of cancer types 14 . To our knowledge, CASC11 is shown to be downregulated in the plasma of CAD patients 15 . However, there is no functional study on the role of CASC11 in CAD.…”

The Emerging Role of Long Non-coding RNAs and Circular RNAs in Coronary Artery Disease

“…Expression of CASC11 has also been decreased in patients with CAD parallel with overexpression of TGF-β1. Functional studies revealed the impact of this lncRNA in the suppression of TGF-β1 expression in endothelial cells ( 19 ).…”

“…Expression of CASC11 has also been decreased in patients with CAD parallel with overexpression of TGF-β1. Functional studies revealed the impact of this lncRNA in the suppression of TGF-β1 expression in endothelial cells ( 19 ). Expression of LEF1-AS1 has been elevated in plasma and tissue samples of CAD patients, whereas expression of its target miRNA, i.e., miR-544a, has been decreased.…”

“…LncRNAs can be used for evaluation of prognosis of CAD patients. For instance, a long-term follow-up study has demonstrated correlation between down-regulation of CASC11 and poor survival of patients with CAD ( 19 ). On the other hand, overexpression of LEF1-AS1 and ANRIL has been shown to be correlated with poor clinical outcome of patients with CAD ( 28 , 44 ).…”